Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PLX PHARMA INC.

(PLXP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

After Hours Watch List Scorecard: PLXP, PPG, ARDX

07/20/2021 | 05:27pm EDT


ę MT Newswires 2021
All news about PLX PHARMA INC.
09/21PLX PHARMA : BWS Financial Initiates Coverage on PLx Pharma With Buy Rating, $29 Price Tar..
MT
09/21PLX PHARMA : Corporate Presentation
PU
09/21PLX PHARMA INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/09PLX PHARMA : to Present at Upcoming Virtual Healthcare Industry Conferences
AQ
08/26PLX PHARMA : Announces Nationwide Rollout of Aspirin Capsules
MT
08/26PLX PHARMA : VAZALORE™ Now on Shelves; National Media Campaign Launches Today
AQ
08/06PLX PHARMA INC. : Entry into a Material Definitive Agreement, Financial Statements and Exh..
AQ
08/06PLX PHARMA : Q2 Loss Widens
MT
08/06PLX PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OP..
AQ
08/06Plx Pharma Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
More news
Analyst Recommendations on PLX PHARMA INC.
More recommendations
Financials (USD)
Sales 2021 9,34 M - -
Net income 2021 -48,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,28x
Yield 2021 -
Capitalization 479 M 479 M -
Capi. / Sales 2021 51,2x
Capi. / Sales 2022 14,6x
Nbr of Employees 10
Free-Float 89,5%
Chart PLX PHARMA INC.
Duration : Period :
PLx Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PLX PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 17,80 $
Average target price 24,00 $
Spread / Average Target 34,8%
EPS Revisions
Managers and Directors
Natasha Giordano President, Chief Executive Officer & Director
Rita M. O'Connor CFO, Head-Manufacturing & Supply Chain
Michael J. Valentino Executive Chairman
Gary S. Balkema Independent Director
Kirk K. Calhoun Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PLX PHARMA INC.222.46%479
GILEAD SCIENCES, INC.23.12%89 936
BIONTECH SE318.73%82 443
WUXI APPTEC CO., LTD.35.75%69 407
REGENERON PHARMACEUTICALS33.91%67 262
VERTEX PHARMACEUTICALS-21.38%48 202